[go: up one dir, main page]

PL1676848T3 - Formy polimorficzne ryfaksyminy jako antybiotyki - Google Patents

Formy polimorficzne ryfaksyminy jako antybiotyki

Info

Publication number
PL1676848T3
PL1676848T3 PL06004220T PL06004220T PL1676848T3 PL 1676848 T3 PL1676848 T3 PL 1676848T3 PL 06004220 T PL06004220 T PL 06004220T PL 06004220 T PL06004220 T PL 06004220T PL 1676848 T3 PL1676848 T3 PL 1676848T3
Authority
PL
Poland
Prior art keywords
rifaximin
antibiotics
polymorphous forms
polymorphous
forms
Prior art date
Application number
PL06004220T
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1676848(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of PL1676848T3 publication Critical patent/PL1676848T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
PL06004220T 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki PL1676848T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e
EP04005541A EP1557421B1 (en) 2003-11-07 2004-03-09 Polymorphous form of rifaximin as antibiotic
EP06004220A EP1676848B1 (en) 2003-11-07 2004-03-09 Polymorphous forms of rifaximin as antibiotics

Publications (1)

Publication Number Publication Date
PL1676848T3 true PL1676848T3 (pl) 2009-07-31

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
PL06004219T PL1676847T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki
PL04005541T PL1557421T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki
PL06004220T PL1676848T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL06004219T PL1676847T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki
PL04005541T PL1557421T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki

Country Status (37)

Country Link
US (5) US7045620B2 (pl)
EP (6) EP1676848B1 (pl)
JP (5) JP2005139161A (pl)
KR (4) KR20050043589A (pl)
CN (4) CN1613858A (pl)
AR (3) AR043547A1 (pl)
AT (3) ATE421965T1 (pl)
AU (2) AU2004200964A1 (pl)
BR (2) BRPI0402382A (pl)
CA (2) CA2460384A1 (pl)
CL (1) CL2004000498A1 (pl)
CO (1) CO5560083A1 (pl)
CY (3) CY1108017T1 (pl)
DE (4) DE602004019296D1 (pl)
DK (3) DK1557421T3 (pl)
ES (3) ES2320161T3 (pl)
HR (2) HRP20040265A2 (pl)
IL (2) IL160798A0 (pl)
IT (1) ITMI20032144A1 (pl)
JO (1) JO2470B1 (pl)
MA (1) MA27069A1 (pl)
MD (1) MD3653G8 (pl)
ME (1) ME00424B (pl)
MX (2) MXPA04002353A (pl)
NO (1) NO334950B1 (pl)
NZ (1) NZ531622A (pl)
PL (3) PL1676847T3 (pl)
PT (3) PT1676848E (pl)
RS (4) RS54568B1 (pl)
RU (1) RU2270200C2 (pl)
SI (3) SI1557421T1 (pl)
TN (2) TNSN04044A1 (pl)
TW (1) TWI285107B (pl)
UA (1) UA86384C2 (pl)
WO (1) WO2005044823A2 (pl)
YU (1) YU24804A (pl)
ZA (1) ZA200401948B (pl)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
DK1698630T3 (da) * 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
AU2007281413B2 (en) 2006-08-02 2013-10-31 Christopher Jahraus Compositions and methods for the treatment of radiation proctosigmoiditis
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8633234B2 (en) * 2006-09-22 2014-01-21 Cipla Limited Rifaximin
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
PL2011486T5 (pl) * 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
CN102015725B (zh) * 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
MX2010009197A (es) 2008-02-26 2010-11-22 Salix Pharmaceuticals Ltd Metodos para tratar padecimientos del intestino.
EP2294012B1 (en) 2008-05-07 2014-07-09 Salix Pharmaceuticals, Ltd. Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease
BRPI0918997A2 (pt) 2008-09-26 2015-12-01 Aska Pharm Co Ltd agente para evitar e/ou tratar um disturbio gastrointestinal funcional.
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
EP4591862A3 (en) 2008-10-02 2025-10-15 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US8916193B2 (en) 2008-12-10 2014-12-23 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
NZ596851A (en) * 2009-06-02 2013-10-25 Salix Pharmaceuticals Ltd Methods of treating hepatic encephalopathy
MX2012002895A (es) * 2009-09-13 2012-05-22 Salix Pharmaceuticals Ltd Metodos para tratar el sindrome de intestino irritado (ibs).
ES2712080T3 (es) * 2009-10-27 2019-05-09 Lupin Ltd Dispersión sólida de rifaximina
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
JP5896380B2 (ja) 2010-02-18 2016-03-30 サリックス ファーマスーティカルズ,リミテッド 感染症を治療するための方法
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
SG185490A1 (en) * 2010-06-03 2012-12-28 Salix Pharmaceuticals Ltd New forms of rifaximin and uses thereof
CA2802874A1 (en) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
US20120077835A1 (en) * 2010-07-12 2012-03-29 Salix Pharmaceuticals, Ltd. Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
EP2672970B1 (en) 2011-02-11 2018-08-01 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
EP2705042A1 (en) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2773205B1 (en) 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
CA2897758A1 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
US20140308350A1 (en) 2013-04-12 2014-10-16 Alfa Wassermann S.P.A. Nsaid administration and related compositions, methods and systems
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
WO2015159275A2 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
MX375805B (es) 2014-05-04 2025-03-07 Salix Pharmaceuticals Inc Microbiota ibs y sus usos.
DK3143027T3 (da) 2014-05-12 2019-08-12 Alfasigma Spa Ny solvatiseret krystalform af rifaximin, fremstilling, sammensætninger og anvendelser heraf
AU2015284782B2 (en) * 2014-06-30 2020-05-07 Salix Pharmaceuticals, Inc. Methods for retreating Irritable Bowel Syndrome (IBS)
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
WO2017162725A1 (en) 2016-03-24 2017-09-28 Sandoz Ag Pharmaceutical composition containing rifaximin alpha & delta
EP3536311B1 (en) 2016-03-24 2021-12-22 Sandoz AG Storage stable composition comprising rifaximin alpha
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
AU2018211305B2 (en) 2017-04-26 2019-07-25 Sandoz Ag Oral dosage form comprising rifaximin in form beta
MX386622B (es) 2017-06-26 2025-03-19 Biofer Spa Derivados de pirido-imidazo rifamicina como agente antibacteriano
WO2020128583A1 (en) * 2018-12-19 2020-06-25 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
WO2021058656A1 (en) 2019-09-24 2021-04-01 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
ATE125541T1 (de) * 1990-06-29 1995-08-15 Lepetit Spa Reine kristalline form von rifapentin.
KR20020071931A (ko) * 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
US6906087B2 (en) * 2000-10-31 2005-06-14 Ciba Specialty Chemicals Corpation Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
US8633234B2 (en) * 2006-09-22 2014-01-21 Cipla Limited Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
PL2011486T5 (pl) 2007-07-06 2016-09-30 Lupin Ltd Farmaceutyczne kompozycje rifaksyminy
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
CN102015725B (zh) 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途

Also Published As

Publication number Publication date
NZ531622A (en) 2004-10-29
JP2014177500A (ja) 2014-09-25
EP1676847A1 (en) 2006-07-05
EP1676848B1 (en) 2009-01-28
MD3653F2 (en) 2008-07-31
US20050101598A1 (en) 2005-05-12
TNSN06069A1 (en) 2007-10-03
US20080132530A1 (en) 2008-06-05
ES2244364T1 (es) 2005-12-16
IL174271A0 (en) 2006-08-01
TNSN04044A1 (en) 2006-06-01
NO20061110L (no) 2006-04-19
DE04005541T1 (de) 2005-12-29
BRPI0407149A8 (pt) 2019-01-15
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
SI1676848T1 (sl) 2009-06-30
ZA200401948B (en) 2004-04-29
RS20150292A1 (en) 2015-10-30
PT1676848E (pt) 2009-04-09
US20050272754A1 (en) 2005-12-08
DE602004006367D1 (de) 2007-06-21
AU2004200964A1 (en) 2005-05-26
WO2005044823A3 (en) 2005-10-27
ITMI20032144A1 (it) 2005-05-08
IL174271A (en) 2010-12-30
CN101260115A (zh) 2008-09-10
HRP20060093A2 (en) 2006-05-31
CY1108964T1 (el) 2014-07-02
EP1557421B1 (en) 2007-05-09
SI1557421T1 (sl) 2007-08-31
RS54571B1 (en) 2016-06-30
ATE421965T1 (de) 2009-02-15
YU24804A (sh) 2006-08-17
EP1682556A2 (en) 2006-07-26
AR081992A2 (es) 2012-10-31
MD3653G8 (ro) 2016-08-31
US8404704B2 (en) 2013-03-26
KR20070113327A (ko) 2007-11-28
ES2320161T3 (es) 2009-05-19
PL1557421T3 (pl) 2007-08-31
WO2005044823A2 (en) 2005-05-19
CY1108017T1 (el) 2013-09-04
DE602004019296D1 (de) 2009-03-19
RS54569B1 (en) 2016-06-30
KR100867751B1 (ko) 2008-11-10
US8173801B2 (en) 2012-05-08
US7045620B2 (en) 2006-05-16
EP2210893A1 (en) 2010-07-28
AU2004287601B8 (en) 2009-03-05
KR100855084B1 (ko) 2008-08-29
CN1613858A (zh) 2005-05-11
JP5199576B2 (ja) 2013-05-15
RU2270200C2 (ru) 2006-02-20
CN1886408B (zh) 2010-06-09
PL1676847T3 (pl) 2009-07-31
HRP20040265A2 (en) 2004-12-31
EP1676847B1 (en) 2009-01-28
RS20060168A (en) 2008-09-29
CY1108909T1 (el) 2014-07-02
RS20150291A1 (en) 2015-10-30
MXPA04002353A (es) 2005-05-11
SI1676847T1 (sl) 2009-06-30
ATE421966T1 (de) 2009-02-15
ES2244364T3 (es) 2007-12-01
CL2004000498A1 (es) 2005-03-11
DE602004006367C5 (de) 2019-04-04
MD20060080A (en) 2006-11-30
CA2460384A1 (en) 2005-05-07
HK1092151A1 (en) 2007-02-02
US7915275B2 (en) 2011-03-29
HK1092150A1 (en) 2007-02-02
AU2004287601B2 (en) 2009-02-26
CN101260115B (zh) 2011-11-23
CA2538546A1 (en) 2005-05-19
DK1676848T3 (da) 2009-05-11
CN101260114A (zh) 2008-09-10
KR100883216B1 (ko) 2009-02-13
RU2004108953A (ru) 2005-10-27
ES2320160T4 (es) 2011-03-09
DE602004019298D1 (de) 2009-03-19
PT1557421E (pt) 2007-07-31
JO2470B1 (en) 2009-01-20
JP2011046738A (ja) 2011-03-10
AU2004287601A1 (en) 2005-05-19
HRP20060093B1 (hr) 2015-12-18
NO334950B1 (no) 2014-08-04
DK1676847T3 (da) 2009-05-11
CN1886408A (zh) 2006-12-27
AR043547A1 (es) 2005-08-03
RS54568B1 (en) 2016-06-30
CN101260114B (zh) 2012-11-28
EP1676848A1 (en) 2006-07-05
AR081991A2 (es) 2012-10-31
DE602004006367T2 (de) 2007-09-06
JP5635376B2 (ja) 2014-12-03
KR20070113326A (ko) 2007-11-28
DK1557421T3 (da) 2007-09-17
JP2007509904A (ja) 2007-04-19
ATE361927T1 (de) 2007-06-15
BRPI0407149A (pt) 2006-02-07
IL160798A0 (en) 2004-08-31
ME00424B (me) 2011-10-10
MXPA06002644A (es) 2006-06-06
JP2005139161A (ja) 2005-06-02
TWI285107B (en) 2007-08-11
TW200515913A (en) 2005-05-16
HK1073657A1 (en) 2005-10-14
US20110160449A1 (en) 2011-06-30
PT1676847E (pt) 2009-04-09
KR20060110737A (ko) 2006-10-25
MA27069A1 (fr) 2004-12-20
US20120059023A1 (en) 2012-03-08
UA86384C2 (uk) 2009-04-27
EP1557421A1 (en) 2005-07-27
BRPI0402382A (pt) 2005-06-28
JP2011057698A (ja) 2011-03-24
KR20050043589A (ko) 2005-05-11
CO5560083A1 (es) 2005-09-30
CA2538546C (en) 2011-04-19

Similar Documents

Publication Publication Date Title
IL174271A0 (en) Polymorphous forms of rifaximin as antibiotics
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
GB0304424D0 (en) Novel compounds
EP1596860A4 (en) NEW CONNECTIONS
EP1620101A4 (en) POLYMORPHS OF CABERGOLIN
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB0315629D0 (en) New uses for antibiotic
GB0304809D0 (en) Novel compounds
GB0302431D0 (en) Novel compounds
GB0302546D0 (en) Novel compounds
HK1093200A (en) Polymorphous forms of rifaximin as antibiotics
ZA200507475B (en) Derivatives of azithromycin
EP1793812A4 (en) ANTIBIOTIC COMPOUND
GB0302008D0 (en) Antibiotic derivatives
PL378080A1 (pl) Sposób wytwarzania K-252A
GB0303767D0 (en) Gentamycin antibiotics
HK1087614A (en) Polymorphs of cabergoline
GB0303874D0 (en) Novel antibacterial compounds
TW568246U (en) Gasifying kiln
PL114147U1 (en) Interior decoration element
GB0301872D0 (en) Novel compounds
GB0300482D0 (en) Novel compounds
GB0301591D0 (en) Novel compounds
GB0301592D0 (en) Novel compounds
GB0301593D0 (en) Novel compounds